Protocol: ADA Bridging ELISA for Use with Anti-Belatacept Antibodies
Anti-Drug Antibody (ADA) Bridging ELISA: for use with Anti-Belatacept Monoclonal Antibodies catalog HCA392, HCA393, and Anti-Abatacept Antibody HCA336
This method provides a procedure for generating an ADA ELISA standard curve with Anti-Belatacept Antibodies HCA392, HCA393, and Anti-Abatacept Antibody HCA336, using belatacept for capture and detection. Belatacept is a fusion protein that only differs from abatacept by two amino acids, hence the Anti-Abatacept Antibody HCA336 recognizes both abatacept and belatacept.
Belatacept is a recombinant, fusion protein drug consisting of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4, also known as CD152), linked to a modified Fc portion of human immunoglobulin G1 (hIgG1). The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.